654-15-9 Usage
Description
3-Benzotriazol-1-yl-propionic Acid, a chemical compound belonging to the benzotriazole family, is characterized by its unique structure and properties. It is a white crystalline solid with a molecular formula of C10H8N2O3 and a molecular weight of 204.18 g/mol. 3-BENZOTRIAZOL-1-YL-PROPIONIC ACID exhibits a wide range of applications in various fields, particularly in biological studies and pharmaceutical research.
Uses
Used in Pharmaceutical Research:
3-Benzotriazol-1-yl-propionic Acid is used as a novel non-iron-chelating inhibitor of prolyl hydroxylase 3 (PHD3) for hypoxia-inducible factor-1 (HIF-1) activation. HIF-1 is a transcription factor that plays a crucial role in the cellular response to hypoxia and is involved in various physiological and pathological processes, including angiogenesis, metabolism, and cell survival. By inhibiting PHD3, this compound can modulate the activity of HIF-1, making it a potential candidate for the development of therapeutic agents targeting hypoxia-related diseases.
Used in Biological Studies:
In the field of biological studies, 3-Benzotriazol-1-yl-propionic Acid serves as a valuable tool for investigating the role of HIF-1 and its regulatory mechanisms. It can be employed in various experimental setups, such as cell culture, gene expression analysis, and animal models, to gain insights into the molecular pathways and signaling events associated with HIF-1 activation. This knowledge can contribute to the understanding of hypoxia-related diseases and the development of targeted therapies.
Used in Drug Discovery and Development:
3-Benzotriazol-1-yl-propionic Acid can be utilized in drug discovery and development processes to identify potential lead compounds and optimize their pharmacological properties. Its unique chemical structure and inhibitory activity against PHD3 make it a promising starting point for the design and synthesis of novel therapeutic agents targeting hypoxia-related conditions. Through medicinal chemistry approaches, researchers can modify its structure to improve its potency, selectivity, and pharmacokinetic properties, ultimately leading to the development of more effective and safer drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 654-15-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,5 and 4 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 654-15:
(5*6)+(4*5)+(3*4)+(2*1)+(1*5)=69
69 % 10 = 9
So 654-15-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H9N3O2/c13-9(14)5-6-12-8-4-2-1-3-7(8)10-11-12/h1-4H,5-6H2,(H,13,14)
654-15-9Relevant articles and documents
DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF
-
Paragraph 0318; 0320, (2015/05/26)
The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.
DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF
-
Page/Page column 94, (2013/08/15)
The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.
SOME BENZOTRIAZOLYLALKANOIC ACIDS AND THEIR AMIDE DERIVATIVES.
SPARATORE,PAGANI
, p. 55 - 75 (2007/10/04)
-
